BioNTech SE is a biotechnology company focused on the development of immunotherapies for cancer and infectious diseases. The company operates through a fully integrated model that combines research, GMP manufacturing, clinical development, and commercialization. Its primary business segments include oncology, where it develops mRNA cancer immunotherapies, immunomodulators, and targeted therapies such as antibody-drug conjugates and bispecific antibodies, and infectious diseases, where it produces vaccines and therapeutics for respiratory viruses, bacteria, and parasites. BioNTech’s marketed product includes the Comirnaty vaccine, developed in partnership with Pfizer. The company holds global rights to the bispecific antibody pumitamig, acquired from Biotheus, and has entered a co-development and co-commercialization agreement with Bristol Myers Squibb for this asset. BioNTech also acquired CureVac N.V. to expand its capabilities in mRNA design and delivery. The company serves markets globally, with a significant presence in the COVID-19 vaccine market. Founded in 2008, BioNTech was formerly known as Petersberg 91, V AG before changing its name in 2008 and converting to a European stock corporation in 2019.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage biontech.com
Sector Healthcare IR page biontech.com/de/de/home.html
Tags
mrna therapeutics, cancer immunotherapy, vaccines, bispecific antibodies, antibody-drug conjugates, infectious diseases, oncology, immunomodulators, car-t cell therapy, clinical development, Comirnaty, pumitamig, BNT327, Biotheus, CureVac N.V., Pfizer, Bristol Myers Squibb
Press page —

Metrics

Valuation  
Market cap $ 23.97B
Market cap (USD) $ 23.97B
P/E -18.11
PEG —
P/BV 1.11
P/S 7.45
P/OCF 46.91
P/FCF 76.15
Dividend yield —
Turnover / mcap —
Returns  
ROE -5.9%
ROI -5.8%
ROIC -5.4%
Profit margin -39.6%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 1.4%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 49
Quality score -55.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 2.87B 2.751B 3.819B 17.311B 18.977B 482.325M 108.589M 127.575M
Net profit -1.136B -665.3M 930.3M 9.434B 10.293B 15.198M -179.056M -48.019M
Free cash flow 280.9M -78.8M 5.122B 13.248B 762.2M -79.507M -237.129M -88.778M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 80.97 103.75 96.96 149.18 218.7 69.74 30.47 —
Price performance 12m -0.16 0.08 -0.3 -0.42 2.16 1.41 — —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Income detail
Research and development expense (EUR) 85.5M 143M 226M 645M 949M 1.54B 1.78B 2.25B 2.1B
↳ 5y CAGR +78.2% +65.6% +58.3% +26.7%
Reported Mar 31, 2020 Mar 31, 2020 Mar 31, 2020 Mar 30, 2021 Mar 30, 2022 Mar 27, 2023 Mar 20, 2024 Mar 10, 2025 Mar 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

MAINZ, Germany, November 10, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that it has entered into an agreement to acquire a US Food and Drug Administration (“FDA”) Priority Review Voucher (“PRV”) from Scholar Rock, Inc. (Nasdaq: SRRK, “Scholar Rock”) for a total cash consideration of $205 million.

A PRV grants FDA priority review for a single application, which reduces the target FDA review timeline and could lead to expedited approval. BioNTech intends to use the PRV to support a future filing of an asset in its late-stage oncology pipeline. The transaction is subject to customary closing conditions, including clearance under the Hart-Scott Rodino (“HSR”) Antitrust Improvements Act.

About BioNTech

BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage.

and Corporate Update

•Delivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung cancer, with pumitamig plus elfetabart drozuntecan

•Advanced the first global Phase 3 clinical trial to evaluate pumitamig in combination with Gilead’s TROP2-directed antibody-drug conjugate sacituzumab govitecan in triple-negative breast cancer, pending regulatory approval

•Presented data demonstrating gotistobart nearly doubled median overall survival versus chemotherapy in previously treated squamous non-small cell lung cancer

•Launched variant-adapted COVID-19 vaccine for the 2026/2027 vaccination season in multiple regions worldwide

•Third quarter 2026 revenues of €1,289.2 million1, adjusted2 R&D expenses of €578.5 million (IFRS R&D expenses of €748.1 million), and adjusted SG&A3 expenses of €178.5 million

•Raised full-year 2026 revenue guidance midpoint and updated range to €1.7–1.9 billion, and maintained strong financial position with cash, cash equivalents and security investments of €16.2 billion4

Conference call and webcast scheduled for November 3, 2026, at 8:00 a.m. EST (2:00 p.m.

Publication date: 10.26.2026

MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE

(Nasdaq: BNTX, “BioNTech”) and DualityBiologics

(Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase 3 clinical trial (NCT06018337

) met its primary endpoint demonstrating a statistically significant, yet modest improvement in progression-free survival (“PFS”) with trastuzumab pamirtecan (BNT323/DB-1303) compared to investigator’s choice of chemotherapy in chemotherapy-naïve patients with HR+/HER2-low metastatic breast cancer who have progressed on endocrine therapy. At this interim analysis for the secondary endpoint of overall survival (“OS”), data were not mature.

A higher rate of interstitial lung disease (“ILD”) was reported in this trial compared to prior trials with trastuzumab pamirtecan, with most cases being Grade 1 and 2. Severe and fatal events were reported in a small proportion of patients (Grade 3-5). Otherwise, the overall safety profile was consistent with prior clinical trials and no new safety signals were observed.

The available efficacy and safety data, as of this data cut-off date, suggest that the potential benefit to patients would be limited in the context of the HR+/HER2-low metastatic breast cancer treatment landscape. The companies will discuss the data and determine next steps.

BioNTech and DualityBio are developing trastuzumab pamirtecan in three ongoing clinical trials, including two global Phase 3 clinical trials, in HR+/HER2-low metastatic breast cancer (NCT06018337

) and in HER2-expressing recurrent endometrial cancer (NCT06340568

), as well as in a global Phase 1/2 clinical trial (NCT05150691

) in patients with advanced/metastatic solid tumors.

About DYNASTY-Breast02

DYNASTY-Breast02 is a global Phase 3 randomized, multi-center, open-label clinical trial in patients living with HR+/HER2-low metastatic breast cancer whose disease has progressed on at least two lines of prior hormone therapy or within six months of first line hormone therapy plus cyclin-dependent kinase (CDK) 4/6 inhibitor in the metastatic setting. The primary endpoint of the clinical trial is PFS with a key secondary endpoint of OS. In the trial, 541 patients with HER2-low expression (IHC 2+/ISH- and IHC 1+) were randomized 1:1 to receive either trastuzumab pamirtecan or investigator's choice single-agent chemotherapy (capecitabine, paclitaxel or nab-paclitaxel).

About trastuzumab pamirtecan

Trastuzumab pamirtecan (BNT323/DB-1303) is a third-generation topoisomerase-1 inhibitor-based ADC targeting HER2 being developed by BioNTech and Duality Biologics. Trastuzumab pamirtecan was built from DualityBio’s proprietary Duality Immune Toxin Antibody Conjugates (“DITAC”) platform. HER2 is a surface-expressed protein on solid tumors and has been linked to the aggressive growth and spread of cancer cells.

Trastuzumab pamirtecan is being evaluated in an ongoing Phase 1/2 trial (NCT05150691

) in patients with advanced/metastatic solid tumors, in Fern-EC-01, a randomized Phase 3 clinical trial (NCT06340568

) evaluating trastuzumab pamirtecan compared with investigator's choice of single agent chemotherapy in previously treated patients with HER2-expressing advanced recurrent endometrial cancer, and in DYNASTY-Breast02, a randomized Phase 3 clinical trial (NCT06018337

) in chemotherapy-naïve patients with HR+/HER2-low metastatic breast cancer who have progressed on endocrine therapy.

Prompts

BioNTech SE (ticker BNTX), listed in United States.

ETFs Holding BioNTech SE

ETF Weight in ETF Shares Market value As of
LGHT 2.88% 767 $ 71.369K Jun 30, 2026
HELX 1.38% 4,156 $ 386.716K Jun 30, 2026
TMED 1.29% 3,188 $ 296.643K Jun 30, 2026
NXTE 1.19% 7,343 $ 683.266K Jun 30, 2026
IALT 0.05% 49,407 $ 4.212M Nov 16, 2026
APIE 0.03% 2,996 $ 304.424K Aug 31, 2026